NCT01813643

A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis

A Multiple-Center, Randomized, Double-Blind Study of Comparison of Risperidone and Aripiprazole for Treatment

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Wei Hao · Academic / Other
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Methamphetamine-associated psychosis (MAP) has been considered a pharmacological or environmental pathogen model of schizophrenia (SCZ) due in part to similarities in clinical presentation (i.e. paranoia, hallucinations, disorganized speech, and negative symptoms), response to treatment (e.g.neuroleptics),and pathologic mechanisms (e.g. central dopaminergic neurotransmission) of both conditions. Both risperidone and aripiprazole are second generation antipsychotics，but have different pharmacological effects of antipsychotic treatment.This study was designed to examine the acute efficacy, safety, and tolerability of risperidone and aripiprazole for patients with MAP.

Detailed description

Methods:A Multiple-Center, Randomized, Double-Blind.

Conditions

• Methamphetamine Dependence

Interventions

Type	Name	Description
DRUG	Risperidone	Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
DRUG	Aripiprazole	Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks

Timeline

• Start date: 2012-07-01
• Primary completion: 2013-12-01
• Completion: 2014-08-01
• First posted: 2013-03-19
• Last updated: 2015-02-04

Locations

1 site across 1 country: China